Thetis Awarded Key Composition of Matter Patents on Resolvin-based Agents

Provides a platform for the development of Resolvin therapies in inflammatory bowel disease and other inflammation disorders

BRANFORD, CT – (January 22, 2019) – Thetis Pharmaceuticals, a privately-held biopharmaceutical company developing novel small molecule therapies based on a class of potent pro-resolving lipid mediators known as Resolvins, announced today that the U.S. Patent and Trademark Office has granted US Patent No. 10,130,719 providing composition of matter patent protection for its TP-317 drug candidate, a novel derivative of Resolvin E1 (RvE1) targeted at inflammatory bowel disease (IBD), and for novel derivatives of D-Series Resolvins. National filings outside of the United States are underway.

Resolvins, part of the superfamily of Specialized Pro-Resolving Lipid Mediators (SPMs), are endogenous lipid autacoids that play a critical role in regulating inflammation resolution and tissue repair throughout the body. By delivering therapeutic doses of Resolvins to activate these intrinsic pathways, Thetis’ drug candidates offer a new approach to treating inflammatory disease by activating intrinsic inflammation resolution pathways without compromising immune function.

Gary Mathias, co-founder and chief executive officer of Thetis said, “This patent expands the intellectual property foundation of our pipeline of innovative Resolvin-based therapies. Despite demonstrating potent pharmacology across multiple inflammatory diseases, Resolvins and other pro-resolving lipid mediators have been hampered by challenges related to their inherent instability and difficult synthesis. Through our HEALER™ technology and innovative synthetic approach, Thetis has unlocked this potent pharmacology by transforming Resolvins into new chemical entities with improved stability and composition of matter patent protection and developing a scalable synthetic approach”.

About Thetis Pharmaceuticals
Thetis Pharmaceuticals is a biopharmaceutical company developing novel lipid-based small molecule therapies for the treatment of inflammatory diseases. Thetis’ HEALER technology platform enables the pharmaceutical development of Resolvins, a novel class of molecules with the potential to transform the treatment of chronic inflammatory diseases. Its lead candidate, TP-317, is a potential first-in-class, safe, oral therapy targeted at ulcerative colitis and Crohn’s disease. Thetis is targeting initial clinical studies in 2020.

For more information, please visit Thetis Pharmaceuticals’ website ( and follow Thetis on Twitter (@thetispharma).

Contact Information
Aaron Mathias
Director of Business Development